#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Discussion
1-1	0-2	3.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=Increased selectivity and efficacy can be achieved by linking cytotoxic anticancer drugs to specific target/carrier molecules .
2-1	14-23	Increased	abstract[2]	new[2]	coref	5-13[37_2]
2-2	24-35	selectivity	abstract[2]	new[2]	_	_
2-3	36-39	and	_	_	_	_
2-4	40-48	efficacy	abstract	new	_	_
2-5	49-52	can	_	_	_	_
2-6	53-55	be	_	_	_	_
2-7	56-64	achieved	_	_	_	_
2-8	65-67	by	_	_	_	_
2-9	68-75	linking	_	_	_	_
2-10	76-85	cytotoxic	substance[5]	new[5]	coref	4-14[32_5]
2-11	86-96	anticancer	abstract|substance[5]	new|new[5]	coref	4-16
2-12	97-102	drugs	substance[5]	new[5]	_	_
2-13	103-105	to	_	_	_	_
2-14	106-114	specific	substance[7]	new[7]	coref	7-4[56_7]
2-15	115-129	target/carrier	substance|substance[7]	new|new[7]	_	_
2-16	130-139	molecules	substance[7]	new[7]	_	_
2-17	140-141	.	_	_	_	_

#Text=Successful examples of this treatment strategy are antibody-drug conjugates , which target cancer cells due to increased expression of specific proteins , and folate conjugates , which utilize a commonly high expression of the folate receptor ( FR ) on the surface of different human cancer cells .
3-1	142-152	Successful	abstract[8]	new[8]	coref	3-8[11_8]
3-2	153-161	examples	abstract[8]	new[8]	_	_
3-3	162-164	of	abstract[8]	new[8]	_	_
3-4	165-169	this	abstract[8]|abstract[10]	new[8]|new[10]	coref	4-5[28_10]
3-5	170-179	treatment	abstract[8]|abstract|abstract[10]	new[8]|new|new[10]	coref	6-12[48_0]
3-6	180-188	strategy	abstract[8]|abstract[10]	new[8]|new[10]	_	_
3-7	189-192	are	_	_	_	_
3-8	193-206	antibody-drug	abstract[11]|abstract[12]	giv[11]|giv[12]	coref|coref	3-8[12_11]|3-24[18_12]
3-9	207-217	conjugates	abstract[11]|abstract[12]	giv[11]|giv[12]	_	_
3-10	218-219	,	abstract[11]|abstract[12]	giv[11]|giv[12]	_	_
3-11	220-225	which	abstract[11]|abstract[12]	giv[11]|giv[12]	_	_
3-12	226-232	target	abstract[11]|abstract[12]|event	giv[11]|giv[12]|new	coref|none	21-1[158_0]|3-12[0_158]
3-13	233-239	cancer	abstract[11]|abstract[12]|abstract|animal[14]	giv[11]|giv[12]|new|new[14]	coref|coref	3-46|3-44[25_14]
3-14	240-245	cells	abstract[11]|abstract[12]|animal[14]	giv[11]|giv[12]|new[14]	_	_
3-15	246-249	due	abstract[12]	giv[12]	_	_
3-16	250-252	to	abstract[12]	giv[12]	_	_
3-17	253-262	increased	abstract[12]|abstract[15]	giv[12]|new[15]	_	_
3-18	263-273	expression	abstract[12]|abstract[15]	giv[12]|new[15]	_	_
3-19	274-276	of	abstract[12]|abstract[15]	giv[12]|new[15]	_	_
3-20	277-285	specific	abstract[12]|abstract[15]|substance[16]	giv[12]|new[15]|new[16]	_	_
3-21	286-294	proteins	abstract[12]|abstract[15]|substance[16]	giv[12]|new[15]|new[16]	_	_
3-22	295-296	,	abstract[12]	giv[12]	_	_
3-23	297-300	and	abstract[12]	giv[12]	_	_
3-24	301-307	folate	abstract[12]|substance|abstract[18]	giv[12]|new|giv[18]	coref|coref	3-35|13-5[96_18]
3-25	308-318	conjugates	abstract[12]|abstract[18]	giv[12]|giv[18]	_	_
3-26	319-320	,	abstract[12]|abstract[18]	giv[12]|giv[18]	_	_
3-27	321-326	which	abstract[12]|abstract[18]	giv[12]|giv[18]	_	_
3-28	327-334	utilize	abstract[12]|abstract[18]	giv[12]|giv[18]	_	_
3-29	335-336	a	abstract[12]|abstract[18]|abstract[19]	giv[12]|giv[18]|new[19]	_	_
3-30	337-345	commonly	abstract[12]|abstract[18]|abstract[19]	giv[12]|giv[18]|new[19]	_	_
3-31	346-350	high	abstract[12]|abstract[18]|abstract[19]	giv[12]|giv[18]|new[19]	_	_
3-32	351-361	expression	abstract[12]|abstract[18]|abstract[19]	giv[12]|giv[18]|new[19]	_	_
3-33	362-364	of	abstract[12]|abstract[18]|abstract[19]	giv[12]|giv[18]|new[19]	_	_
3-34	365-368	the	abstract[12]|abstract[18]|abstract[19]|abstract[21]	giv[12]|giv[18]|new[19]|new[21]	appos	3-38[0_21]
3-35	369-375	folate	abstract[12]|abstract[18]|abstract[19]|substance|abstract[21]	giv[12]|giv[18]|new[19]|giv|new[21]	_	_
3-36	376-384	receptor	abstract[12]|abstract[18]|abstract[19]|abstract[21]	giv[12]|giv[18]|new[19]|new[21]	_	_
3-37	385-386	(	abstract[12]|abstract[18]|abstract[19]	giv[12]|giv[18]|new[19]	_	_
3-38	387-389	FR	abstract[12]|abstract[18]|abstract[19]|abstract	giv[12]|giv[18]|new[19]|giv	_	_
3-39	390-391	)	abstract[12]|abstract[18]|abstract[19]	giv[12]|giv[18]|new[19]	_	_
3-40	392-394	on	abstract[12]|abstract[18]|abstract[19]	giv[12]|giv[18]|new[19]	_	_
3-41	395-398	the	abstract[12]|abstract[18]|abstract[19]|place[23]	giv[12]|giv[18]|new[19]|new[23]	_	_
3-42	399-406	surface	abstract[12]|abstract[18]|abstract[19]|place[23]	giv[12]|giv[18]|new[19]|new[23]	_	_
3-43	407-409	of	abstract[12]|abstract[18]|abstract[19]|place[23]	giv[12]|giv[18]|new[19]|new[23]	_	_
3-44	410-419	different	abstract[12]|abstract[18]|abstract[19]|place[23]|animal[25]	giv[12]|giv[18]|new[19]|new[23]|giv[25]	coref	5-30[44_25]
3-45	420-425	human	abstract[12]|abstract[18]|abstract[19]|place[23]|animal[25]	giv[12]|giv[18]|new[19]|new[23]|giv[25]	_	_
3-46	426-432	cancer	abstract[12]|abstract[18]|abstract[19]|place[23]|abstract|animal[25]	giv[12]|giv[18]|new[19]|new[23]|giv|giv[25]	coref	5-31
3-47	433-438	cells	abstract[12]|abstract[18]|abstract[19]|place[23]|animal[25]	giv[12]|giv[18]|new[19]|new[23]|giv[25]	_	_
3-48	439-440	.	_	_	_	_

#Text=Warburg effect targeting is another promising strategy for the design and synthesis of new cytotoxic anticancer drugs .
4-1	441-448	Warburg	place|abstract[27]	new|new[27]	coref|coref	8-4|8-4[60_27]
4-2	449-455	effect	abstract[27]	new[27]	_	_
4-3	456-465	targeting	_	_	_	_
4-4	466-468	is	_	_	_	_
4-5	469-476	another	abstract[28]	giv[28]	_	_
4-6	477-486	promising	abstract[28]	giv[28]	_	_
4-7	487-495	strategy	abstract[28]	giv[28]	_	_
4-8	496-499	for	abstract[28]	giv[28]	_	_
4-9	500-503	the	abstract[28]|abstract[29]	giv[28]|new[29]	_	_
4-10	504-510	design	abstract[28]|abstract[29]	giv[28]|new[29]	_	_
4-11	511-514	and	abstract[28]	giv[28]	_	_
4-12	515-524	synthesis	abstract[28]|abstract[30]	giv[28]|new[30]	_	_
4-13	525-527	of	abstract[28]|abstract[30]	giv[28]|new[30]	_	_
4-14	528-531	new	abstract[28]|abstract[30]|substance[32]	giv[28]|new[30]|giv[32]	coref	5-9[36_32]
4-15	532-541	cytotoxic	abstract[28]|abstract[30]|substance[32]	giv[28]|new[30]|giv[32]	_	_
4-16	542-552	anticancer	abstract[28]|abstract[30]|abstract|substance[32]	giv[28]|new[30]|giv|giv[32]	_	_
4-17	553-558	drugs	abstract[28]|abstract[30]|substance[32]	giv[28]|new[30]|giv[32]	_	_
4-18	559-560	.	_	_	_	_

#Text=Here , the conjugation of sugar residues to cytotoxic drugs shall increase selectivity to cancerous tissues and reduce side effects in patients due to a higher sugar uptake by the cancer cells .
5-1	561-565	Here	_	_	_	_
5-2	566-567	,	_	_	_	_
5-3	568-571	the	event[33]	new[33]	_	_
5-4	572-583	conjugation	event[33]	new[33]	_	_
5-5	584-586	of	event[33]	new[33]	_	_
5-6	587-592	sugar	event[33]|substance|substance[35]	new[33]|new|new[35]	coref|coref	5-27|12-14[91_35]
5-7	593-601	residues	event[33]|substance[35]	new[33]|new[35]	_	_
5-8	602-604	to	event[33]	new[33]	_	_
5-9	605-614	cytotoxic	event[33]|substance[36]	new[33]|giv[36]	_	_
5-10	615-620	drugs	event[33]|substance[36]	new[33]|giv[36]	_	_
5-11	621-626	shall	_	_	_	_
5-12	627-635	increase	_	_	_	_
5-13	636-647	selectivity	abstract[37]	giv[37]	coref	11-12[82_37]
5-14	648-650	to	abstract[37]	giv[37]	_	_
5-15	651-660	cancerous	abstract[37]|object[38]	giv[37]|new[38]	_	_
5-16	661-668	tissues	abstract[37]|object[38]	giv[37]|new[38]	_	_
5-17	669-672	and	_	_	_	_
5-18	673-679	reduce	_	_	_	_
5-19	680-684	side	abstract[39]	new[39]	coref	10-20[77_39]
5-20	685-692	effects	abstract[39]	new[39]	_	_
5-21	693-695	in	_	_	_	_
5-22	696-704	patients	person	new	_	_
5-23	705-708	due	_	_	_	_
5-24	709-711	to	_	_	_	_
5-25	712-713	a	abstract[42]	new[42]	coref	14-33[112_42]
5-26	714-720	higher	abstract[42]	new[42]	_	_
5-27	721-726	sugar	substance|abstract[42]	giv|new[42]	_	_
5-28	727-733	uptake	abstract[42]	new[42]	_	_
5-29	734-736	by	abstract[42]	new[42]	_	_
5-30	737-740	the	abstract[42]|animal[44]	new[42]|giv[44]	coref	9-17[73_44]
5-31	741-747	cancer	abstract[42]|abstract|animal[44]	new[42]|giv|giv[44]	coref	6-15[53_0]
5-32	748-753	cells	abstract[42]|animal[44]	new[42]|giv[44]	_	_
5-33	754-755	.	_	_	_	_

#Text=To date one sugar-conjugated molecule glufosfamide is in clinical development for the treatment of lung , ovary , pancreatic , brain and CNS cancer as well as soft tissue sarcoma .
6-1	756-758	To	_	_	_	_
6-2	759-763	date	_	_	_	_
6-3	764-767	one	substance[45]	new[45]	coref	15-10[118_45]
6-4	768-784	sugar-conjugated	substance[45]	new[45]	_	_
6-5	785-793	molecule	substance[45]	new[45]	_	_
6-6	794-806	glufosfamide	substance	new	_	_
6-7	807-809	is	_	_	_	_
6-8	810-812	in	_	_	_	_
6-9	813-821	clinical	abstract[47]	new[47]	_	_
6-10	822-833	development	abstract[47]	new[47]	_	_
6-11	834-837	for	abstract[47]	new[47]	_	_
6-12	838-841	the	abstract[47]|abstract[48]	new[47]|giv[48]	_	_
6-13	842-851	treatment	abstract[47]|abstract[48]	new[47]|giv[48]	_	_
6-14	852-854	of	abstract[47]|abstract[48]	new[47]|giv[48]	_	_
6-15	855-859	lung	abstract[47]|abstract[48]|object|abstract[53]	new[47]|giv[48]|new|giv[53]	coref	8-2[58_53]
6-16	860-861	,	abstract[47]|abstract[48]|abstract[53]	new[47]|giv[48]|giv[53]	_	_
6-17	862-867	ovary	abstract[47]|abstract[48]|place|abstract[53]	new[47]|giv[48]|new|giv[53]	_	_
6-18	868-869	,	abstract[47]|abstract[48]|abstract[53]	new[47]|giv[48]|giv[53]	_	_
6-19	870-880	pancreatic	abstract[47]|abstract[48]|abstract[53]	new[47]|giv[48]|giv[53]	_	_
6-20	881-882	,	abstract[47]|abstract[48]|abstract[53]	new[47]|giv[48]|giv[53]	_	_
6-21	883-888	brain	abstract[47]|abstract[48]|object|abstract[53]	new[47]|giv[48]|new|giv[53]	_	_
6-22	889-892	and	abstract[47]|abstract[48]|abstract[53]	new[47]|giv[48]|giv[53]	_	_
6-23	893-896	CNS	abstract[47]|abstract[48]|place|abstract[53]	new[47]|giv[48]|new|giv[53]	_	_
6-24	897-903	cancer	abstract[47]|abstract[48]|abstract[53]	new[47]|giv[48]|giv[53]	_	_
6-25	904-906	as	abstract[47]|abstract[48]	new[47]|giv[48]	_	_
6-26	907-911	well	abstract[47]|abstract[48]	new[47]|giv[48]	_	_
6-27	912-914	as	abstract[47]|abstract[48]	new[47]|giv[48]	_	_
6-28	915-919	soft	abstract[47]|abstract[48]|object[54]|abstract[55]	new[47]|giv[48]|new[54]|new[55]	coref	26-18[220_54]
6-29	920-926	tissue	abstract[47]|abstract[48]|object[54]|abstract[55]	new[47]|giv[48]|new[54]|new[55]	_	_
6-30	927-934	sarcoma	abstract[47]|abstract[48]|abstract[55]	new[47]|giv[48]|new[55]	_	_
6-31	935-936	.	_	_	_	_

#Text=In addition , different sugar-conjugated molecules are currently evaluated preclinically .
7-1	937-939	In	_	_	_	_
7-2	940-948	addition	_	_	_	_
7-3	949-950	,	_	_	_	_
7-4	951-960	different	substance[56]	giv[56]	coref	12-3[87_56]
7-5	961-977	sugar-conjugated	substance[56]	giv[56]	_	_
7-6	978-987	molecules	substance[56]	giv[56]	_	_
7-7	988-991	are	_	_	_	_
7-8	992-1001	currently	_	_	_	_
7-9	1002-1011	evaluated	_	_	_	_
7-10	1012-1025	preclinically	_	_	_	_
7-11	1026-1027	.	_	_	_	_

#Text=In prostate cancer Warburg effect was observed specifically in metastatic tumors which makes glucose-derived chemotherapeutics promising in the treatment of metastatic CRPC .
8-1	1028-1030	In	_	_	_	_
8-2	1031-1039	prostate	place|abstract[58]	new|giv[58]	coref|coref	9-18|9-18[72_58]
8-3	1040-1046	cancer	abstract[58]	giv[58]	_	_
8-4	1047-1054	Warburg	place|abstract[60]	giv|giv[60]	coref|coref	11-6|11-5[81_60]
8-5	1055-1061	effect	abstract[60]	giv[60]	_	_
8-6	1062-1065	was	_	_	_	_
8-7	1066-1074	observed	_	_	_	_
8-8	1075-1087	specifically	_	_	_	_
8-9	1088-1090	in	_	_	_	_
8-10	1091-1101	metastatic	object[61]	new[61]	coref	26-14[219_61]
8-11	1102-1108	tumors	object[61]	new[61]	_	_
8-12	1109-1114	which	object[61]	new[61]	_	_
8-13	1115-1120	makes	object[61]	new[61]	_	_
8-14	1121-1136	glucose-derived	object[61]|abstract[62]	new[61]|new[62]	_	_
8-15	1137-1154	chemotherapeutics	object[61]|abstract[62]	new[61]|new[62]	_	_
8-16	1155-1164	promising	object[61]	new[61]	_	_
8-17	1165-1167	in	_	_	_	_
8-18	1168-1171	the	abstract[63]	new[63]	coref	26-11[217_63]
8-19	1172-1181	treatment	abstract[63]	new[63]	_	_
8-20	1182-1184	of	abstract[63]	new[63]	_	_
8-21	1185-1195	metastatic	abstract[63]|abstract[64]	new[63]|new[64]	_	_
8-22	1196-1200	CRPC	abstract[63]|abstract[64]	new[63]|new[64]	_	_
8-23	1201-1202	.	_	_	_	_

#Text=In our research , we found the derivatives of natural 1,4-naphtoquinone compounds to be active in drug-resistant prostate cancer cells .
9-1	1203-1205	In	_	_	_	_
9-2	1206-1209	our	person|abstract[66]	acc|new[66]	ana	9-5
9-3	1210-1218	research	abstract[66]	new[66]	_	_
9-4	1219-1220	,	_	_	_	_
9-5	1221-1223	we	person	giv	ana	11-3
9-6	1224-1229	found	_	_	_	_
9-7	1230-1233	the	substance[68]	new[68]	coref	21-9[162_68]
9-8	1234-1245	derivatives	substance[68]	new[68]	_	_
9-9	1246-1248	of	substance[68]	new[68]	_	_
9-10	1249-1256	natural	substance[68]|substance[70]	new[68]|new[70]	coref	10-9[75_70]
9-11	1257-1274	1,4-naphtoquinone	substance[68]|abstract|substance[70]	new[68]|new|new[70]	coref	12-10
9-12	1275-1284	compounds	substance[68]|substance[70]	new[68]|new[70]	_	_
9-13	1285-1287	to	_	_	_	_
9-14	1288-1290	be	_	_	_	_
9-15	1291-1297	active	_	_	_	_
9-16	1298-1300	in	_	_	_	_
9-17	1301-1315	drug-resistant	animal[73]	giv[73]	coref	10-16[76_73]
9-18	1316-1324	prostate	place|abstract[72]|animal[73]	giv|giv[72]|giv[73]	coref|coref	20-15|20-15[154_72]
9-19	1325-1331	cancer	abstract[72]|animal[73]	giv[72]|giv[73]	_	_
9-20	1332-1337	cells	animal[73]	giv[73]	_	_
9-21	1338-1339	.	_	_	_	_

#Text=Preliminary data , however , have shown that these substances are also rather cytotoxic for non-cancerous cells , suggesting undesired side effects in vivo .
10-1	1340-1351	Preliminary	abstract[74]	new[74]	_	_
10-2	1352-1356	data	abstract[74]	new[74]	_	_
10-3	1357-1358	,	_	_	_	_
10-4	1359-1366	however	_	_	_	_
10-5	1367-1368	,	_	_	_	_
10-6	1369-1373	have	_	_	_	_
10-7	1374-1379	shown	_	_	_	_
10-8	1380-1384	that	_	_	_	_
10-9	1385-1390	these	substance[75]	giv[75]	coref	11-15[83_75]
10-10	1391-1401	substances	substance[75]	giv[75]	_	_
10-11	1402-1405	are	_	_	_	_
10-12	1406-1410	also	_	_	_	_
10-13	1411-1417	rather	_	_	_	_
10-14	1418-1427	cytotoxic	_	_	_	_
10-15	1428-1431	for	_	_	_	_
10-16	1432-1445	non-cancerous	animal[76]	giv[76]	coref	11-18[85_76]
10-17	1446-1451	cells	animal[76]	giv[76]	_	_
10-18	1452-1453	,	_	_	_	_
10-19	1454-1464	suggesting	_	_	_	_
10-20	1465-1474	undesired	abstract[77]	giv[77]	_	_
10-21	1475-1479	side	abstract[77]	giv[77]	_	_
10-22	1480-1487	effects	abstract[77]	giv[77]	_	_
10-23	1488-1490	in	_	_	_	_
10-24	1491-1495	vivo	abstract	new	coref	25-16
10-25	1496-1497	.	_	_	_	_

#Text=Therefore , we utilized the Warburg effect in order to increase the selectivity of the compounds towards tumor cells .
11-1	1498-1507	Therefore	_	_	_	_
11-2	1508-1509	,	_	_	_	_
11-3	1510-1512	we	person	giv	ana	12-1
11-4	1513-1521	utilized	_	_	_	_
11-5	1522-1525	the	abstract[81]	giv[81]	coref	21-5[160_81]
11-6	1526-1533	Warburg	place|abstract[81]	giv|giv[81]	coref	21-6
11-7	1534-1540	effect	abstract[81]	giv[81]	_	_
11-8	1541-1543	in	_	_	_	_
11-9	1544-1549	order	_	_	_	_
11-10	1550-1552	to	_	_	_	_
11-11	1553-1561	increase	_	_	_	_
11-12	1562-1565	the	abstract[82]	giv[82]	coref	20-10[152_82]
11-13	1566-1577	selectivity	abstract[82]	giv[82]	_	_
11-14	1578-1580	of	abstract[82]	giv[82]	_	_
11-15	1581-1584	the	abstract[82]|substance[83]	giv[82]|giv[83]	coref	20-6[151_83]
11-16	1585-1594	compounds	abstract[82]|substance[83]	giv[82]|giv[83]	_	_
11-17	1595-1602	towards	abstract[82]	giv[82]	_	_
11-18	1603-1608	tumor	abstract[82]|animal|animal[85]	giv[82]|new|giv[85]	coref	21-40[173_85]
11-19	1609-1614	cells	abstract[82]|animal[85]	giv[82]|giv[85]	_	_
11-20	1615-1616	.	_	_	_	_

#Text=We synthesized hybrid molecules , which contain selected natural 1,4-naphtoquinone moieties conjugated with glucose residues via non-glycoside bond at C6 position .
12-1	1617-1619	We	person	giv	ana	17-15
12-2	1620-1631	synthesized	_	_	_	_
12-3	1632-1638	hybrid	substance[87]	giv[87]	coref	14-38[113_87]
12-4	1639-1648	molecules	substance[87]	giv[87]	_	_
12-5	1649-1650	,	substance[87]	giv[87]	_	_
12-6	1651-1656	which	substance[87]	giv[87]	_	_
12-7	1657-1664	contain	substance[87]	giv[87]	_	_
12-8	1665-1673	selected	substance[87]|substance[89]	giv[87]|new[89]	_	_
12-9	1674-1681	natural	substance[87]|substance[89]	giv[87]|new[89]	_	_
12-10	1682-1699	1,4-naphtoquinone	substance[87]|abstract|substance[89]	giv[87]|giv|new[89]	_	_
12-11	1700-1708	moieties	substance[87]|substance[89]	giv[87]|new[89]	_	_
12-12	1709-1719	conjugated	substance[87]|substance[89]	giv[87]|new[89]	_	_
12-13	1720-1724	with	substance[87]|substance[89]	giv[87]|new[89]	_	_
12-14	1725-1732	glucose	substance[87]|substance[89]|substance|substance[91]	giv[87]|new[89]|new|giv[91]	coref|coref	13-17|19-11[148_91]
12-15	1733-1741	residues	substance[87]|substance[89]|substance[91]	giv[87]|new[89]|giv[91]	_	_
12-16	1742-1745	via	substance[87]|substance[89]	giv[87]|new[89]	_	_
12-17	1746-1759	non-glycoside	substance[87]|substance[89]|abstract[92]	giv[87]|new[89]|new[92]	coref	15-17[120_92]
12-18	1760-1764	bond	substance[87]|substance[89]|abstract[92]	giv[87]|new[89]|new[92]	_	_
12-19	1765-1767	at	substance[87]|substance[89]|abstract[92]	giv[87]|new[89]|new[92]	_	_
12-20	1768-1770	C6	substance[87]|substance[89]|abstract[92]|object|abstract[94]	giv[87]|new[89]|new[92]|new|new[94]	coref|coref	14-14[106_94]|15-7
12-21	1771-1779	position	substance[87]|substance[89]|abstract[92]|abstract[94]	giv[87]|new[89]|new[92]|new[94]	_	_
12-22	1780-1781	.	_	_	_	_

#Text=The non-glycoside nature of the conjugates was chosen in order to provide the highest affinity to glucose transporters located in the cellular membrane .
13-1	1782-1785	The	abstract[95]	new[95]	_	_
13-2	1786-1799	non-glycoside	abstract[95]	new[95]	_	_
13-3	1800-1806	nature	abstract[95]	new[95]	_	_
13-4	1807-1809	of	abstract[95]	new[95]	_	_
13-5	1810-1813	the	abstract[95]|abstract[96]	new[95]|giv[96]	coref	19-8[146_96]
13-6	1814-1824	conjugates	abstract[95]|abstract[96]	new[95]|giv[96]	_	_
13-7	1825-1828	was	_	_	_	_
13-8	1829-1835	chosen	_	_	_	_
13-9	1836-1838	in	_	_	_	_
13-10	1839-1844	order	_	_	_	_
13-11	1845-1847	to	_	_	_	_
13-12	1848-1855	provide	_	_	_	_
13-13	1856-1859	the	abstract[97]	new[97]	ana	14-1[0_97]
13-14	1860-1867	highest	abstract[97]	new[97]	_	_
13-15	1868-1876	affinity	abstract[97]	new[97]	_	_
13-16	1877-1879	to	abstract[97]	new[97]	_	_
13-17	1880-1887	glucose	abstract[97]|substance|person[99]	new[97]|giv|new[99]	coref	15-10
13-18	1888-1900	transporters	abstract[97]|person[99]	new[97]|new[99]	_	_
13-19	1901-1908	located	abstract[97]|person[99]	new[97]|new[99]	_	_
13-20	1909-1911	in	abstract[97]|person[99]	new[97]|new[99]	_	_
13-21	1912-1915	the	abstract[97]|person[99]|place[100]	new[97]|new[99]|new[100]	_	_
13-22	1916-1924	cellular	abstract[97]|person[99]|place[100]	new[97]|new[99]|new[100]	_	_
13-23	1925-1933	membrane	abstract[97]|person[99]|place[100]	new[97]|new[99]|new[100]	_	_
13-24	1934-1935	.	_	_	_	_

#Text=It is known that the presence of free unsubstituted glycoside hydroxyl ( at C1 position ) is important for the stabilization of hydrogen bonding interactions with GLUT-1 and therefore is required for the successful cellular uptake of the sugar-conjugated molecules .
14-1	1936-1938	It	abstract	giv	coref	16-4[124_0]
14-2	1939-1941	is	_	_	_	_
14-3	1942-1947	known	_	_	_	_
14-4	1948-1952	that	_	_	_	_
14-5	1953-1956	the	abstract[102]	new[102]	_	_
14-6	1957-1965	presence	abstract[102]	new[102]	_	_
14-7	1966-1968	of	abstract[102]	new[102]	_	_
14-8	1969-1973	free	abstract[102]|substance[104]	new[102]|new[104]	coref	15-4[114_104]
14-9	1974-1987	unsubstituted	abstract[102]|substance[104]	new[102]|new[104]	_	_
14-10	1988-1997	glycoside	abstract[102]|place|substance[104]	new[102]|new|new[104]	_	_
14-11	1998-2006	hydroxyl	abstract[102]|substance[104]	new[102]|new[104]	_	_
14-12	2007-2008	(	abstract[102]	new[102]	_	_
14-13	2009-2011	at	abstract[102]	new[102]	_	_
14-14	2012-2014	C1	abstract[102]|object|abstract[106]	new[102]|new|giv[106]	coref	15-7[116_106]
14-15	2015-2023	position	abstract[102]|abstract[106]	new[102]|giv[106]	_	_
14-16	2024-2025	)	abstract[102]	new[102]	_	_
14-17	2026-2028	is	_	_	_	_
14-18	2029-2038	important	_	_	_	_
14-19	2039-2042	for	_	_	_	_
14-20	2043-2046	the	event[107]	new[107]	_	_
14-21	2047-2060	stabilization	event[107]	new[107]	_	_
14-22	2061-2063	of	event[107]	new[107]	_	_
14-23	2064-2072	hydrogen	event[107]|substance|abstract[109]|abstract[110]	new[107]|new|new[109]|new[110]	coref|coref	15-17|15-16[121_110]
14-24	2073-2080	bonding	event[107]|abstract[109]|abstract[110]	new[107]|new[109]|new[110]	_	_
14-25	2081-2093	interactions	event[107]|abstract[110]	new[107]|new[110]	_	_
14-26	2094-2098	with	event[107]|abstract[110]	new[107]|new[110]	_	_
14-27	2099-2105	GLUT-1	event[107]|abstract[110]|abstract	new[107]|new[110]|new	coref	16-12
14-28	2106-2109	and	_	_	_	_
14-29	2110-2119	therefore	_	_	_	_
14-30	2120-2122	is	_	_	_	_
14-31	2123-2131	required	_	_	_	_
14-32	2132-2135	for	_	_	_	_
14-33	2136-2139	the	abstract[112]	giv[112]	coref	21-70[184_112]
14-34	2140-2150	successful	abstract[112]	giv[112]	_	_
14-35	2151-2159	cellular	abstract[112]	giv[112]	_	_
14-36	2160-2166	uptake	abstract[112]	giv[112]	_	_
14-37	2167-2169	of	abstract[112]	giv[112]	_	_
14-38	2170-2173	the	abstract[112]|substance[113]	giv[112]|giv[113]	_	_
14-39	2174-2190	sugar-conjugated	abstract[112]|substance[113]	giv[112]|giv[113]	_	_
14-40	2191-2200	molecules	abstract[112]|substance[113]	giv[112]|giv[113]	_	_
14-41	2201-2202	.	_	_	_	_

#Text=In contrast , the hydroxyl at C6 position of glucose molecule is not relevant for the hydrogen bond interactions and therefore it ’s substitution may be more tolerable .
15-1	2203-2205	In	_	_	_	_
15-2	2206-2214	contrast	_	_	_	_
15-3	2215-2216	,	_	_	_	_
15-4	2217-2220	the	substance[114]	giv[114]	_	_
15-5	2221-2229	hydroxyl	substance[114]	giv[114]	_	_
15-6	2230-2232	at	substance[114]	giv[114]	_	_
15-7	2233-2235	C6	substance[114]|object|abstract[116]	giv[114]|giv|giv[116]	_	_
15-8	2236-2244	position	substance[114]|abstract[116]	giv[114]|giv[116]	_	_
15-9	2245-2247	of	substance[114]|abstract[116]	giv[114]|giv[116]	_	_
15-10	2248-2255	glucose	substance[114]|abstract[116]|substance|substance[118]	giv[114]|giv[116]|giv|giv[118]	ana|coref	15-22[0_118]|16-7[125_0]
15-11	2256-2264	molecule	substance[114]|abstract[116]|substance[118]	giv[114]|giv[116]|giv[118]	_	_
15-12	2265-2267	is	_	_	_	_
15-13	2268-2271	not	_	_	_	_
15-14	2272-2280	relevant	_	_	_	_
15-15	2281-2284	for	_	_	_	_
15-16	2285-2288	the	abstract[121]	giv[121]	_	_
15-17	2289-2297	hydrogen	substance|abstract[120]|abstract[121]	giv|giv[120]|giv[121]	_	_
15-18	2298-2302	bond	abstract[120]|abstract[121]	giv[120]|giv[121]	_	_
15-19	2303-2315	interactions	abstract[121]	giv[121]	_	_
15-20	2316-2319	and	_	_	_	_
15-21	2320-2329	therefore	_	_	_	_
15-22	2330-2332	it	substance|event[123]	giv|new[123]	coref	23-28[202_0]
15-23	2333-2335	’s	event[123]	new[123]	_	_
15-24	2336-2348	substitution	event[123]	new[123]	_	_
15-25	2349-2352	may	_	_	_	_
15-26	2353-2355	be	_	_	_	_
15-27	2356-2360	more	_	_	_	_
15-28	2361-2370	tolerable	_	_	_	_
15-29	2371-2372	.	_	_	_	_

#Text=In fact , the affinity of glucose with substituted C6-OH to GLUT-1 was reported to be almost equal to its unsubstituted analogues .
16-1	2373-2375	In	_	_	_	_
16-2	2376-2380	fact	_	_	_	_
16-3	2381-2382	,	_	_	_	_
16-4	2383-2386	the	abstract[124]	giv[124]	_	_
16-5	2387-2395	affinity	abstract[124]	giv[124]	_	_
16-6	2396-2398	of	abstract[124]	giv[124]	_	_
16-7	2399-2406	glucose	abstract[124]|substance[125]	giv[124]|giv[125]	coref	17-12[132_125]
16-8	2407-2411	with	abstract[124]|substance[125]	giv[124]|giv[125]	_	_
16-9	2412-2423	substituted	abstract[124]|substance[125]|substance[126]	giv[124]|giv[125]|new[126]	ana	16-20[0_126]
16-10	2424-2429	C6-OH	abstract[124]|substance[125]|substance[126]	giv[124]|giv[125]|new[126]	_	_
16-11	2430-2432	to	abstract[124]	giv[124]	_	_
16-12	2433-2439	GLUT-1	abstract[124]|abstract	giv[124]|giv	coref	21-38
16-13	2440-2443	was	_	_	_	_
16-14	2444-2452	reported	_	_	_	_
16-15	2453-2455	to	_	_	_	_
16-16	2456-2458	be	_	_	_	_
16-17	2459-2465	almost	_	_	_	_
16-18	2466-2471	equal	_	_	_	_
16-19	2472-2474	to	_	_	_	_
16-20	2475-2478	its	substance|object[129]	giv|new[129]	_	_
16-21	2479-2492	unsubstituted	object[129]	new[129]	_	_
16-22	2493-2502	analogues	object[129]	new[129]	_	_
16-23	2503-2504	.	_	_	_	_

#Text=Therefore , instead of a conventional glycosylation reaction ( results in C1-substituted glucose ) we applied a new reaction of alkylation of 2-hydroxy-1,4-naphthoquinones with 6-deoxy-6-iodo-1,2:3,5-di-O- isopropylidene-α-D-glucofuranose ( results in a C6-substituted glucose ) .
17-1	2505-2514	Therefore	_	_	_	_
17-2	2515-2516	,	_	_	_	_
17-3	2517-2524	instead	_	_	_	_
17-4	2525-2527	of	_	_	_	_
17-5	2528-2529	a	event[131]	new[131]	coref	18-9[141_131]
17-6	2530-2542	conventional	event[131]	new[131]	_	_
17-7	2543-2556	glycosylation	abstract|event[131]	new|new[131]	_	_
17-8	2557-2565	reaction	event[131]	new[131]	_	_
17-9	2566-2567	(	_	_	_	_
17-10	2568-2575	results	_	_	_	_
17-11	2576-2578	in	_	_	_	_
17-12	2579-2593	C1-substituted	substance[132]	giv[132]	coref	17-30[138_132]
17-13	2594-2601	glucose	substance[132]	giv[132]	_	_
17-14	2602-2603	)	_	_	_	_
17-15	2604-2606	we	person	giv	ana	18-19
17-16	2607-2614	applied	_	_	_	_
17-17	2615-2616	a	event[134]	new[134]	coref	18-1[139_134]
17-18	2617-2620	new	event[134]	new[134]	_	_
17-19	2621-2629	reaction	event[134]	new[134]	_	_
17-20	2630-2632	of	event[134]	new[134]	_	_
17-21	2633-2643	alkylation	event[134]|substance[135]	new[134]|new[135]	_	_
17-22	2644-2646	of	event[134]|substance[135]	new[134]|new[135]	_	_
17-23	2647-2676	2-hydroxy-1,4-naphthoquinones	event[134]|substance[135]|abstract	new[134]|new[135]|new	_	_
17-24	2677-2681	with	event[134]|substance[135]	new[134]|new[135]	_	_
17-25	2682-2710	6-deoxy-6-iodo-1,2:3,5-di-O-	event[134]|substance[135]|abstract[137]	new[134]|new[135]|new[137]	_	_
17-26	2711-2743	isopropylidene-α-D-glucofuranose	event[134]|substance[135]|abstract[137]	new[134]|new[135]|new[137]	_	_
17-27	2744-2745	(	_	_	_	_
17-28	2746-2753	results	_	_	_	_
17-29	2754-2756	in	_	_	_	_
17-30	2757-2758	a	substance[138]	giv[138]	coref	19-17[0_138]
17-31	2759-2773	C6-substituted	substance[138]	giv[138]	_	_
17-32	2774-2781	glucose	substance[138]	giv[138]	_	_
17-33	2782-2783	)	_	_	_	_
17-34	2784-2785	.	_	_	_	_

#Text=This reaction was more efficient in comparison with transesterification reaction of 2-methoxy-1,4-naphthoquinones , which was recently discovered by us .
18-1	2786-2790	This	event[139]	giv[139]	_	_
18-2	2791-2799	reaction	event[139]	giv[139]	_	_
18-3	2800-2803	was	_	_	_	_
18-4	2804-2808	more	_	_	_	_
18-5	2809-2818	efficient	_	_	_	_
18-6	2819-2821	in	_	_	_	_
18-7	2822-2832	comparison	_	_	_	_
18-8	2833-2837	with	_	_	_	_
18-9	2838-2857	transesterification	abstract|event[141]	new|giv[141]	_	_
18-10	2858-2866	reaction	event[141]	giv[141]	_	_
18-11	2867-2869	of	event[141]	giv[141]	_	_
18-12	2870-2899	2-methoxy-1,4-naphthoquinones	event[141]|substance	giv[141]|new	_	_
18-13	2900-2901	,	event[141]	giv[141]	_	_
18-14	2902-2907	which	event[141]	giv[141]	_	_
18-15	2908-2911	was	event[141]	giv[141]	_	_
18-16	2912-2920	recently	event[141]	giv[141]	_	_
18-17	2921-2931	discovered	event[141]	giv[141]	_	_
18-18	2932-2934	by	event[141]	giv[141]	_	_
18-19	2935-2937	us	event[141]|person	giv[141]|giv	ana	19-3
18-20	2938-2939	.	_	_	_	_

#Text=Thus , we synthesized a series of 6-(1,4-naphtoquinonyl)-D-glucose conjugates containing diprotected , monoprotected , or unprotected glucose residues .
19-1	2940-2944	Thus	_	_	_	_
19-2	2945-2946	,	_	_	_	_
19-3	2947-2949	we	person	giv	ana	20-4
19-4	2950-2961	synthesized	_	_	_	_
19-5	2962-2963	a	abstract[145]	new[145]	_	_
19-6	2964-2970	series	abstract[145]	new[145]	_	_
19-7	2971-2973	of	abstract[145]	new[145]	_	_
19-8	2974-3006	6-(1,4-naphtoquinonyl)-D-glucose	abstract[145]|abstract[146]	new[145]|giv[146]	coref	21-31[168_146]
19-9	3007-3017	conjugates	abstract[145]|abstract[146]	new[145]|giv[146]	_	_
19-10	3018-3028	containing	abstract[145]|abstract[146]	new[145]|giv[146]	_	_
19-11	3029-3040	diprotected	abstract[145]|abstract[146]|substance[148]	new[145]|giv[146]|giv[148]	_	_
19-12	3041-3042	,	abstract[145]|abstract[146]|substance[148]	new[145]|giv[146]|giv[148]	_	_
19-13	3043-3056	monoprotected	abstract[145]|abstract[146]|substance[148]	new[145]|giv[146]|giv[148]	_	_
19-14	3057-3058	,	abstract[145]|abstract[146]|substance[148]	new[145]|giv[146]|giv[148]	_	_
19-15	3059-3061	or	abstract[145]|abstract[146]|substance[148]	new[145]|giv[146]|giv[148]	_	_
19-16	3062-3073	unprotected	abstract[145]|abstract[146]|substance[148]	new[145]|giv[146]|giv[148]	_	_
19-17	3074-3081	glucose	abstract[145]|abstract[146]|substance|substance[148]	new[145]|giv[146]|giv|giv[148]	coref	21-12
19-18	3082-3090	residues	abstract[145]|abstract[146]|substance[148]	new[145]|giv[146]|giv[148]	_	_
19-19	3091-3092	.	_	_	_	_

#Text=In line with our hypotheses the glucose-conjugated compounds revealed higher selectivity towards five human prostate cancer cell lines compared with five non-cancerous lines .
20-1	3093-3095	In	_	_	_	_
20-2	3096-3100	line	_	_	_	_
20-3	3101-3105	with	_	_	_	_
20-4	3106-3109	our	person|abstract[150]	giv|new[150]	_	_
20-5	3110-3120	hypotheses	abstract[150]	new[150]	_	_
20-6	3121-3124	the	substance[151]	giv[151]	coref	21-66[182_151]
20-7	3125-3143	glucose-conjugated	substance[151]	giv[151]	_	_
20-8	3144-3153	compounds	substance[151]	giv[151]	_	_
20-9	3154-3162	revealed	_	_	_	_
20-10	3163-3169	higher	abstract[152]	giv[152]	_	_
20-11	3170-3181	selectivity	abstract[152]	giv[152]	_	_
20-12	3182-3189	towards	abstract[152]	giv[152]	_	_
20-13	3190-3194	five	abstract[152]|object[156]	giv[152]|new[156]	coref	20-21[157_156]
20-14	3195-3200	human	abstract[152]|object[156]	giv[152]|new[156]	_	_
20-15	3201-3209	prostate	abstract[152]|place|abstract[154]|object[156]	giv[152]|giv|giv[154]|new[156]	coref|coref	21-41|21-41[172_154]
20-16	3210-3216	cancer	abstract[152]|abstract[154]|object[156]	giv[152]|giv[154]|new[156]	_	_
20-17	3217-3221	cell	abstract[152]|place|object[156]	giv[152]|new|new[156]	_	_
20-18	3222-3227	lines	abstract[152]|object[156]	giv[152]|new[156]	_	_
20-19	3228-3236	compared	abstract[152]|object[156]	giv[152]|new[156]	_	_
20-20	3237-3241	with	abstract[152]|object[156]	giv[152]|new[156]	_	_
20-21	3242-3246	five	abstract[152]|object[156]|object[157]	giv[152]|new[156]|giv[157]	_	_
20-22	3247-3260	non-cancerous	abstract[152]|object[156]|object[157]	giv[152]|new[156]|giv[157]	_	_
20-23	3261-3266	lines	abstract[152]|object[156]|object[157]	giv[152]|new[156]|giv[157]	_	_
20-24	3267-3268	.	_	_	_	_

#Text=The successful targeting of the Warburg effect by the newly synthesized glucose derivatives is strongly suggested by the following findings : ( a ) correlation of cytotoxicity and selectivity of the synthesized conjugates with higher expression of GLUT-1 in human prostate cancer cells ; ( b ) inhibition of cytotoxicity of the conjugates by addition of glucose to the media ; c ) ability of the compounds to inhibit a glucose uptake by cancer cells .
21-1	3269-3272	The	event[158]	new[158]	_	_
21-2	3273-3283	successful	event[158]	new[158]	_	_
21-3	3284-3293	targeting	event[158]	new[158]	_	_
21-4	3294-3296	of	event[158]	new[158]	_	_
21-5	3297-3300	the	event[158]|abstract[160]	new[158]|giv[160]	coref	25-10[211_160]
21-6	3301-3308	Warburg	event[158]|place|abstract[160]	new[158]|giv|giv[160]	coref	25-11
21-7	3309-3315	effect	event[158]|abstract[160]	new[158]|giv[160]	_	_
21-8	3316-3318	by	event[158]	new[158]	_	_
21-9	3319-3322	the	event[158]|substance[162]	new[158]|giv[162]	coref	23-17[200_162]
21-10	3323-3328	newly	event[158]|substance[162]	new[158]|giv[162]	_	_
21-11	3329-3340	synthesized	event[158]|substance[162]	new[158]|giv[162]	_	_
21-12	3341-3348	glucose	event[158]|substance|substance[162]	new[158]|giv|giv[162]	coref	21-57
21-13	3349-3360	derivatives	event[158]|substance[162]	new[158]|giv[162]	_	_
21-14	3361-3363	is	_	_	_	_
21-15	3364-3372	strongly	_	_	_	_
21-16	3373-3382	suggested	_	_	_	_
21-17	3383-3385	by	_	_	_	_
21-18	3386-3389	the	abstract[163]	new[163]	appos	21-25[164_163]
21-19	3390-3399	following	abstract[163]	new[163]	_	_
21-20	3400-3408	findings	abstract[163]	new[163]	_	_
21-21	3409-3410	:	abstract[163]	new[163]	_	_
21-22	3411-3412	(	abstract[163]	new[163]	_	_
21-23	3413-3414	a	abstract[163]	new[163]	_	_
21-24	3415-3416	)	abstract[163]	new[163]	_	_
21-25	3417-3428	correlation	abstract[164]|abstract[165]	giv[164]|giv[165]	appos|appos	21-25[165_164]|21-48[174_165]
21-26	3429-3431	of	abstract[164]|abstract[165]	giv[164]|giv[165]	_	_
21-27	3432-3444	cytotoxicity	abstract[164]|abstract[165]|abstract	giv[164]|giv[165]|new	_	_
21-28	3445-3448	and	abstract[164]|abstract[165]	giv[164]|giv[165]	_	_
21-29	3449-3460	selectivity	abstract[164]|abstract[165]|abstract[167]	giv[164]|giv[165]|new[167]	coref	22-21[0_167]
21-30	3461-3463	of	abstract[164]|abstract[165]|abstract[167]	giv[164]|giv[165]|new[167]	_	_
21-31	3464-3467	the	abstract[164]|abstract[165]|abstract[167]|abstract[168]	giv[164]|giv[165]|new[167]|giv[168]	coref	21-52[176_168]
21-32	3468-3479	synthesized	abstract[164]|abstract[165]|abstract[167]|abstract[168]	giv[164]|giv[165]|new[167]|giv[168]	_	_
21-33	3480-3490	conjugates	abstract[164]|abstract[165]|abstract[167]|abstract[168]	giv[164]|giv[165]|new[167]|giv[168]	_	_
21-34	3491-3495	with	abstract[164]|abstract[165]	giv[164]|giv[165]	_	_
21-35	3496-3502	higher	abstract[164]|abstract[165]|abstract[169]	giv[164]|giv[165]|new[169]	_	_
21-36	3503-3513	expression	abstract[164]|abstract[165]|abstract[169]	giv[164]|giv[165]|new[169]	_	_
21-37	3514-3516	of	abstract[164]|abstract[165]|abstract[169]	giv[164]|giv[165]|new[169]	_	_
21-38	3517-3523	GLUT-1	abstract[164]|abstract[165]|abstract[169]|abstract	giv[164]|giv[165]|new[169]|giv	_	_
21-39	3524-3526	in	abstract[164]|abstract[165]|abstract[169]	giv[164]|giv[165]|new[169]	_	_
21-40	3527-3532	human	abstract[164]|abstract[165]|abstract[169]|animal[173]	giv[164]|giv[165]|new[169]|giv[173]	coref	21-74[186_173]
21-41	3533-3541	prostate	abstract[164]|abstract[165]|abstract[169]|place|abstract[172]|animal[173]	giv[164]|giv[165]|new[169]|giv|giv[172]|giv[173]	coref|coref	21-74[0_172]|24-8
21-42	3542-3548	cancer	abstract[164]|abstract[165]|abstract[169]|abstract[172]|animal[173]	giv[164]|giv[165]|new[169]|giv[172]|giv[173]	_	_
21-43	3549-3554	cells	abstract[164]|abstract[165]|abstract[169]|animal[173]	giv[164]|giv[165]|new[169]|giv[173]	_	_
21-44	3555-3556	;	abstract[165]	giv[165]	_	_
21-45	3557-3558	(	abstract[165]	giv[165]	_	_
21-46	3559-3560	b	abstract[165]	giv[165]	_	_
21-47	3561-3562	)	abstract[165]	giv[165]	_	_
21-48	3563-3573	inhibition	abstract[165]|abstract[174]	giv[165]|giv[174]	_	_
21-49	3574-3576	of	abstract[165]|abstract[174]	giv[165]|giv[174]	_	_
21-50	3577-3589	cytotoxicity	abstract[165]|abstract[174]|abstract[175]	giv[165]|giv[174]|new[175]	coref	23-12[0_175]
21-51	3590-3592	of	abstract[165]|abstract[174]|abstract[175]	giv[165]|giv[174]|new[175]	_	_
21-52	3593-3596	the	abstract[165]|abstract[174]|abstract[175]|abstract[176]	giv[165]|giv[174]|new[175]|giv[176]	_	_
21-53	3597-3607	conjugates	abstract[165]|abstract[174]|abstract[175]|abstract[176]	giv[165]|giv[174]|new[175]|giv[176]	_	_
21-54	3608-3610	by	abstract[165]|abstract[174]	giv[165]|giv[174]	_	_
21-55	3611-3619	addition	abstract[165]|abstract[174]|abstract[177]	giv[165]|giv[174]|new[177]	_	_
21-56	3620-3622	of	abstract[165]|abstract[174]|abstract[177]	giv[165]|giv[174]|new[177]	_	_
21-57	3623-3630	glucose	abstract[165]|abstract[174]|abstract[177]|substance	giv[165]|giv[174]|new[177]|giv	coref	21-71
21-58	3631-3633	to	abstract[165]|abstract[174]|abstract[177]	giv[165]|giv[174]|new[177]	_	_
21-59	3634-3637	the	abstract[165]|abstract[174]|abstract[177]|substance[179]	giv[165]|giv[174]|new[177]|new[179]	_	_
21-60	3638-3643	media	abstract[165]|abstract[174]|abstract[177]|substance[179]	giv[165]|giv[174]|new[177]|new[179]	_	_
21-61	3644-3645	;	_	_	_	_
21-62	3646-3647	c	abstract	new	_	_
21-63	3648-3649	)	_	_	_	_
21-64	3650-3657	ability	abstract[181]	new[181]	_	_
21-65	3658-3660	of	abstract[181]	new[181]	_	_
21-66	3661-3664	the	abstract[181]|substance[182]	new[181]|giv[182]	_	_
21-67	3665-3674	compounds	abstract[181]|substance[182]	new[181]|giv[182]	_	_
21-68	3675-3677	to	abstract[181]	new[181]	_	_
21-69	3678-3685	inhibit	abstract[181]	new[181]	_	_
21-70	3686-3687	a	abstract[181]|abstract[184]	new[181]|giv[184]	_	_
21-71	3688-3695	glucose	abstract[181]|substance|abstract[184]	new[181]|giv|giv[184]	coref	22-12
21-72	3696-3702	uptake	abstract[181]|abstract[184]	new[181]|giv[184]	_	_
21-73	3703-3705	by	abstract[181]|abstract[184]	new[181]|giv[184]	_	_
21-74	3706-3712	cancer	abstract[181]|abstract[184]|abstract|animal[186]	new[181]|giv[184]|giv|giv[186]	coref|coref	24-7[205_186]|26-6[216_0]
21-75	3713-3718	cells	abstract[181]|abstract[184]|animal[186]	new[181]|giv[184]|giv[186]	_	_
21-76	3719-3720	.	_	_	_	_

#Text=In general , the binding of the quinone core with the glucose moiety lead to an increased water solubility and selectivity .
22-1	3721-3723	In	_	_	_	_
22-2	3724-3731	general	_	_	_	_
22-3	3732-3733	,	_	_	_	_
22-4	3734-3737	the	event[187]	new[187]	_	_
22-5	3738-3745	binding	event[187]	new[187]	_	_
22-6	3746-3748	of	event[187]	new[187]	_	_
22-7	3749-3752	the	event[187]|object[189]	new[187]|new[189]	_	_
22-8	3753-3760	quinone	event[187]|substance|object[189]	new[187]|new|new[189]	_	_
22-9	3761-3765	core	event[187]|object[189]	new[187]|new[189]	_	_
22-10	3766-3770	with	event[187]	new[187]	_	_
22-11	3771-3774	the	event[187]|substance[191]	new[187]|new[191]	_	_
22-12	3775-3782	glucose	event[187]|substance|substance[191]	new[187]|giv|new[191]	coref	24-23
22-13	3783-3789	moiety	event[187]|substance[191]	new[187]|new[191]	_	_
22-14	3790-3794	lead	_	_	_	_
22-15	3795-3797	to	_	_	_	_
22-16	3798-3800	an	abstract[193]	new[193]	_	_
22-17	3801-3810	increased	abstract[193]	new[193]	_	_
22-18	3811-3816	water	substance|abstract[193]	new|new[193]	_	_
22-19	3817-3827	solubility	abstract[193]	new[193]	_	_
22-20	3828-3831	and	_	_	_	_
22-21	3832-3843	selectivity	abstract	giv	ana	23-7
22-22	3844-3845	.	_	_	_	_

#Text=However , at the same time it resulted in an absolute cytotoxicity decrease when compared to methoxy derivatives , most probably due to the increased polarity of the molecule .
23-1	3846-3853	However	_	_	_	_
23-2	3854-3855	,	_	_	_	_
23-3	3856-3858	at	_	_	_	_
23-4	3859-3862	the	time[195]	new[195]	_	_
23-5	3863-3867	same	time[195]	new[195]	_	_
23-6	3868-3872	time	time[195]	new[195]	_	_
23-7	3873-3875	it	abstract	giv	_	_
23-8	3876-3884	resulted	_	_	_	_
23-9	3885-3887	in	_	_	_	_
23-10	3888-3890	an	event[198]	new[198]	_	_
23-11	3891-3899	absolute	event[198]	new[198]	_	_
23-12	3900-3912	cytotoxicity	abstract|event[198]	giv|new[198]	_	_
23-13	3913-3921	decrease	event[198]	new[198]	_	_
23-14	3922-3926	when	_	_	_	_
23-15	3927-3935	compared	_	_	_	_
23-16	3936-3938	to	_	_	_	_
23-17	3939-3946	methoxy	abstract|substance[200]	new|giv[200]	_	_
23-18	3947-3958	derivatives	substance[200]	giv[200]	_	_
23-19	3959-3960	,	_	_	_	_
23-20	3961-3965	most	_	_	_	_
23-21	3966-3974	probably	_	_	_	_
23-22	3975-3978	due	_	_	_	_
23-23	3979-3981	to	_	_	_	_
23-24	3982-3985	the	abstract[201]	new[201]	ana	24-1[0_201]
23-25	3986-3995	increased	abstract[201]	new[201]	_	_
23-26	3996-4004	polarity	abstract[201]	new[201]	_	_
23-27	4005-4007	of	abstract[201]	new[201]	_	_
23-28	4008-4011	the	abstract[201]|substance[202]	new[201]|giv[202]	_	_
23-29	4012-4020	molecule	abstract[201]|substance[202]	new[201]|giv[202]	_	_
23-30	4021-4022	.	_	_	_	_

#Text=It should also be noted that normal prostate cells are known to have an active glycolysis and also consume significant amount of glucose ( reviewed in ) .
24-1	4023-4025	It	abstract	giv	_	_
24-2	4026-4032	should	_	_	_	_
24-3	4033-4037	also	_	_	_	_
24-4	4038-4040	be	_	_	_	_
24-5	4041-4046	noted	_	_	_	_
24-6	4047-4051	that	_	_	_	_
24-7	4052-4058	normal	animal[205]	giv[205]	coref	25-3[209_205]
24-8	4059-4067	prostate	place|animal[205]	giv|giv[205]	coref	26-7
24-9	4068-4073	cells	animal[205]	giv[205]	_	_
24-10	4074-4077	are	_	_	_	_
24-11	4078-4083	known	_	_	_	_
24-12	4084-4086	to	_	_	_	_
24-13	4087-4091	have	_	_	_	_
24-14	4092-4094	an	substance[206]	new[206]	_	_
24-15	4095-4101	active	substance[206]	new[206]	_	_
24-16	4102-4112	glycolysis	substance[206]	new[206]	_	_
24-17	4113-4116	and	_	_	_	_
24-18	4117-4121	also	_	_	_	_
24-19	4122-4129	consume	_	_	_	_
24-20	4130-4141	significant	substance[207]	new[207]	_	_
24-21	4142-4148	amount	substance[207]	new[207]	_	_
24-22	4149-4151	of	substance[207]	new[207]	_	_
24-23	4152-4159	glucose	substance[207]|substance	new[207]|giv	_	_
24-24	4160-4161	(	_	_	_	_
24-25	4162-4170	reviewed	_	_	_	_
24-26	4171-4173	in	_	_	_	_
24-27	4174-4175	)	_	_	_	_
24-28	4176-4177	.	_	_	_	_

#Text=Thus , these cells may also be affected by the Warburg effect targeting therapeutics in vivo .
25-1	4178-4182	Thus	_	_	_	_
25-2	4183-4184	,	_	_	_	_
25-3	4185-4190	these	animal[209]	giv[209]	_	_
25-4	4191-4196	cells	animal[209]	giv[209]	_	_
25-5	4197-4200	may	_	_	_	_
25-6	4201-4205	also	_	_	_	_
25-7	4206-4208	be	_	_	_	_
25-8	4209-4217	affected	_	_	_	_
25-9	4218-4220	by	_	_	_	_
25-10	4221-4224	the	abstract[211]	giv[211]	_	_
25-11	4225-4232	Warburg	place|abstract[211]	giv|giv[211]	_	_
25-12	4233-4239	effect	abstract[211]	giv[211]	_	_
25-13	4240-4249	targeting	abstract[211]	giv[211]	_	_
25-14	4250-4262	therapeutics	abstract[211]|abstract	giv[211]|new	_	_
25-15	4263-4265	in	abstract[211]	giv[211]	_	_
25-16	4266-4270	vivo	abstract[211]|abstract	giv[211]|giv	_	_
25-17	4271-4272	.	_	_	_	_

#Text=However , frequently patients with advanced prostate cancer have had local treatment for their primary tumors leaving no vital tissue behind .
26-1	4273-4280	However	_	_	_	_
26-2	4281-4282	,	_	_	_	_
26-3	4283-4293	frequently	_	_	_	_
26-4	4294-4302	patients	person[214]	new[214]	ana	26-14[0_214]
26-5	4303-4307	with	person[214]	new[214]	_	_
26-6	4308-4316	advanced	person[214]|abstract[216]	new[214]|giv[216]	_	_
26-7	4317-4325	prostate	person[214]|place|abstract[216]	new[214]|giv|giv[216]	coref	27-8
26-8	4326-4332	cancer	person[214]|abstract[216]	new[214]|giv[216]	_	_
26-9	4333-4337	have	_	_	_	_
26-10	4338-4341	had	_	_	_	_
26-11	4342-4347	local	abstract[217]	giv[217]	_	_
26-12	4348-4357	treatment	abstract[217]	giv[217]	_	_
26-13	4358-4361	for	abstract[217]	giv[217]	_	_
26-14	4362-4367	their	abstract[217]|person|object[219]	giv[217]|giv|giv[219]	coref	27-2[221_0]
26-15	4368-4375	primary	abstract[217]|object[219]	giv[217]|giv[219]	_	_
26-16	4376-4382	tumors	abstract[217]|object[219]	giv[217]|giv[219]	_	_
26-17	4383-4390	leaving	abstract[217]|object[219]	giv[217]|giv[219]	_	_
26-18	4391-4393	no	abstract[217]|object[219]|object[220]	giv[217]|giv[219]|giv[220]	coref	27-6[224_220]
26-19	4394-4399	vital	abstract[217]|object[219]|object[220]	giv[217]|giv[219]|giv[220]	_	_
26-20	4400-4406	tissue	abstract[217]|object[219]|object[220]	giv[217]|giv[219]|giv[220]	_	_
26-21	4407-4413	behind	abstract[217]|object[219]	giv[217]|giv[219]	_	_
26-22	4414-4415	.	_	_	_	_

#Text=In the patients cytoreduction of the remaining prostate tissue maybe a pleasant side effect in order to avoid local complications .
27-1	4416-4418	In	_	_	_	_
27-2	4419-4422	the	person[221]	giv[221]	_	_
27-3	4423-4431	patients	person[221]	giv[221]	_	_
27-4	4432-4445	cytoreduction	abstract[222]	new[222]	coref	27-11[226_222]
27-5	4446-4448	of	abstract[222]	new[222]	_	_
27-6	4449-4452	the	abstract[222]|object[224]	new[222]|giv[224]	_	_
27-7	4453-4462	remaining	abstract[222]|object[224]	new[222]|giv[224]	_	_
27-8	4463-4471	prostate	abstract[222]|place|object[224]	new[222]|giv|giv[224]	_	_
27-9	4472-4478	tissue	abstract[222]|object[224]	new[222]|giv[224]	_	_
27-10	4479-4484	maybe	_	_	_	_
27-11	4485-4486	a	abstract[226]	giv[226]	_	_
27-12	4487-4495	pleasant	abstract[226]	giv[226]	_	_
27-13	4496-4500	side	abstract|abstract[226]	new|giv[226]	_	_
27-14	4501-4507	effect	abstract[226]	giv[226]	_	_
27-15	4508-4510	in	abstract[226]	giv[226]	_	_
27-16	4511-4516	order	abstract[226]	giv[226]	_	_
27-17	4517-4519	to	abstract[226]	giv[226]	_	_
27-18	4520-4525	avoid	abstract[226]	giv[226]	_	_
27-19	4526-4531	local	abstract[226]|abstract[227]	giv[226]|new[227]	_	_
27-20	4532-4545	complications	abstract[226]|abstract[227]	giv[226]|new[227]	_	_
27-21	4546-4547	.	_	_	_	_
